Detailed regulatory analyses.
FDA's 503B proposal (April 30, 2026)
FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list. No final decision yet.
Compounding framework
503A vs 503B, USP standards, state authority.
State pharmacy boards
How state boards license and inspect compounding pharmacies, and how to look one up.